PFE vs SLRX

Pfizer Inc. remains a mature, large-cap pharmaceutical company with no material changes since the last analysis that would indicate a path to 10x growth. The company faces ongoing headwinds from declining COVID product sales and patent cliffs. While a settlement extended Vyndamax exclusivity, this is insufficient to offset broader challenges. Upcoming Q1 2026 earnings are projected to show a ~20% ...

SLRX (Salarius Pharmaceuticals, Inc.) was acquired by VolitionRx Limited (VNRX) on October 18, 2023, and subsequently delisted. As of today, 2026-03-29, it does not exist as an independent publicly traded entity with any growth prospects. The quoted current price of $7.62 is an anomaly for a delisted ticker and does not reflect a liquid, investable asset. There have been no material changes since ...